PatentJul 10, 2026, 08:01 AM
Greenland Mines Secures Australian Patent for Neuromuscular Gene Therapy
AI Summary
Greenland Mines Ltd's Biotech Division announced that IP Australia has granted Australian Patent No. 2023252508, titled "Treatment of Neuromuscular Diseases via Gene Therapy that Expresses Klotho Protein." This patent covers technology exclusively licensed by the company, protecting the use of human gene therapy with a muscle-cell specific promoter for treating motor impairment. CEO Dr. Joseph Sinkule stated that this strengthens the intellectual property protecting their Klotho-based therapeutic platform and supports the advancement of KLTO-202 toward clinical development for ALS and other debilitating neuromuscular diseases.
Key Highlights
- Greenland Mines' Biotech Division granted Australian Patent No. 2023252508.
- Patent covers gene therapy for neuromuscular diseases using Klotho protein expression.
- Technology exclusively licensed from Universitat Autònoma de Barcelona researchers.
- Protects use of muscle-cell specific promoter linked to human Klotho s-KL protein.
- Includes claims for neuronal cells, iPSC, AAV, and non-viral cellular delivery systems.
- Strengthens IP for Klotho-based therapeutic platform, advancing KLTO-202 for ALS.
- Neuromuscular diseases include ALS, SMA, MS, and muscular dystrophies.
- The patent expands the company's global intellectual property estate.
Price Impact
More from GRML